Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	intracellularly gated calcium channel activity	RYR1 RYR3 MCOLN2	1.10e-05	18	49	3	GO:0015278
GeneOntologyMolecularFunction	ryanodine-sensitive calcium-release channel activity	RYR1 RYR3	3.53e-05	4	49	2	GO:0005219
GeneOntologyMolecularFunction	ligand-gated calcium channel activity	RYR1 RYR3 MCOLN2	5.95e-05	31	49	3	GO:0099604
GeneOntologyMolecularFunction	intracellularly ligand-gated monoatomic ion channel activity	RYR1 RYR3 MCOLN2	7.19e-05	33	49	3	GO:0005217
GeneOntologyMolecularFunction	calcium-induced calcium release activity	RYR1 RYR3	8.79e-05	6	49	2	GO:0048763
GeneOntologyMolecularFunction	monoatomic cation channel activity	SLC24A5 KCNB2 SHROOM2 RYR1 RYR3 MCOLN2	1.84e-04	343	49	6	GO:0005261
GeneOntologyMolecularFunction	calcium channel activity	SLC24A5 RYR1 RYR3 MCOLN2	2.81e-04	129	49	4	GO:0005262
GeneOntologyMolecularFunction	ligand-gated monoatomic cation channel activity	SHROOM2 RYR1 RYR3 MCOLN2	3.84e-04	140	49	4	GO:0099094
GeneOntologyMolecularFunction	calcium ion transmembrane transporter activity	SLC24A5 RYR1 RYR3 MCOLN2	5.11e-04	151	49	4	GO:0015085
GeneOntologyMolecularFunction	DNA nuclease activity	DNASE2B DCLRE1B DICER1	5.96e-04	67	49	3	GO:0004536
GeneOntologyMolecularFunction	S-adenosylmethionine-dependent methyltransferase activity	NSUN4 PRDM8 NDUFAF5 NTMT1	8.33e-04	172	49	4	GO:0008757
GeneOntologyMolecularFunction	monoatomic ion channel activity	SLC24A5 KCNB2 SHROOM2 RYR1 RYR3 MCOLN2	8.65e-04	459	49	6	GO:0005216
GeneOntologyMolecularFunction	metal ion transmembrane transporter activity	SLC24A5 KCNB2 SHROOM2 RYR1 RYR3 MCOLN2	9.25e-04	465	49	6	GO:0046873
GeneOntologyMolecularFunction	catalytic activity, acting on a nucleic acid	NSUN4 DNASE2B ATAD5 DHX57 DCLRE1B ERI1 DICER1	9.38e-04	645	49	7	GO:0140640
GeneOntologyMolecularFunction	ligand-gated monoatomic ion channel activity	SHROOM2 RYR1 RYR3 MCOLN2	1.28e-03	193	49	4	GO:0015276
GeneOntologyMolecularFunction	gated channel activity	KCNB2 SHROOM2 RYR1 RYR3 MCOLN2	1.33e-03	334	49	5	GO:0022836
GeneOntologyMolecularFunction	ligand-gated channel activity	SHROOM2 RYR1 RYR3 MCOLN2	1.38e-03	197	49	4	GO:0022834
GeneOntologyMolecularFunction	channel activity	SLC24A5 KCNB2 SHROOM2 RYR1 RYR3 MCOLN2	1.72e-03	525	49	6	GO:0015267
GeneOntologyMolecularFunction	passive transmembrane transporter activity	SLC24A5 KCNB2 SHROOM2 RYR1 RYR3 MCOLN2	1.74e-03	526	49	6	GO:0022803
GeneOntologyMolecularFunction	methyltransferase activity	NSUN4 PRDM8 NDUFAF5 NTMT1	1.83e-03	213	49	4	GO:0008168
GeneOntologyMolecularFunction	histone kinase activity	CDK1 CDK2	2.14e-03	28	49	2	GO:0035173
GeneOntologyMolecularFunction	transferase activity, transferring one-carbon groups	NSUN4 PRDM8 NDUFAF5 NTMT1	2.20e-03	224	49	4	GO:0016741
GeneOntologyMolecularFunction	histone modifying activity	PRDM8 NTMT1 CDK1 CDK2	2.38e-03	229	49	4	GO:0140993
GeneOntologyMolecularFunction	cyclin-dependent protein serine/threonine kinase activity	CDK1 CDK2	2.46e-03	30	49	2	GO:0004693
GeneOntologyMolecularFunction	cyclin-dependent protein kinase activity	CDK1 CDK2	2.46e-03	30	49	2	GO:0097472
GeneOntologyMolecularFunction	nuclease activity	DNASE2B DCLRE1B ERI1 DICER1	2.46e-03	231	49	4	GO:0004518
GeneOntologyMolecularFunction	cyclin binding	CDK1 CDK2	3.33e-03	35	49	2	GO:0030332
GeneOntologyMolecularFunction	peptidase regulator activity	GBP2 SERPINC1 DMWD SERPINA9	3.61e-03	257	49	4	GO:0061134
GeneOntologyMolecularFunction	catalytic activity, acting on DNA	DNASE2B ATAD5 DCLRE1B DICER1	3.86e-03	262	49	4	GO:0140097
GeneOntologyMolecularFunction	inorganic cation transmembrane transporter activity	SLC24A5 KCNB2 SHROOM2 RYR1 RYR3 MCOLN2	4.15e-03	627	49	6	GO:0022890
GeneOntologyMolecularFunction	DNA endonuclease activity	DNASE2B DICER1	5.23e-03	44	49	2	GO:0004520
GeneOntologyMolecularFunction	monoatomic cation transmembrane transporter activity	SLC24A5 KCNB2 SHROOM2 RYR1 RYR3 MCOLN2	5.48e-03	664	49	6	GO:0008324
GeneOntologyMolecularFunction	phosphatidylinositol-3-phosphate binding	ZFYVE19 WDR45B	6.19e-03	48	49	2	GO:0032266
GeneOntologyCellularComponent	smooth endoplasmic reticulum	APOB RYR1 RYR3	1.93e-04	46	51	3	GO:0005790
GeneOntologyCellularComponent	junctional membrane complex	RYR1 RYR3	2.08e-04	9	51	2	GO:0030314
Domain	Ryanrecept_TM4-6	RYR1 RYR3	2.10e-05	3	50	2	IPR009460
Domain	RyR	RYR1 RYR3	2.10e-05	3	50	2	PF02026
Domain	Ryanodine_rcpt	RYR1 RYR3	2.10e-05	3	50	2	IPR003032
Domain	RR_TM4-6	RYR1 RYR3	2.10e-05	3	50	2	PF06459
Domain	Ryan_recept	RYR1 RYR3	2.10e-05	3	50	2	IPR013333
Domain	RIH_assoc	RYR1 RYR3	1.05e-04	6	50	2	PF08454
Domain	RIH_assoc-dom	RYR1 RYR3	1.05e-04	6	50	2	IPR013662
Domain	RIH_dom	RYR1 RYR3	1.05e-04	6	50	2	IPR000699
Domain	Ins145_P3_rcpt	RYR1 RYR3	1.05e-04	6	50	2	IPR014821
Domain	Ryanodine_recept-rel	RYR1 RYR3	1.05e-04	6	50	2	IPR015925
Domain	-	RYR1 RYR3	1.05e-04	6	50	2	1.25.10.30
Domain	RYDR_ITPR	RYR1 RYR3	1.05e-04	6	50	2	PF01365
Domain	Ins145_P3_rec	RYR1 RYR3	1.05e-04	6	50	2	PF08709
Domain	Ion_trans_dom	KCNB2 RYR1 RYR3 MCOLN2	2.44e-04	114	50	4	IPR005821
Domain	Ion_trans	KCNB2 RYR1 RYR3 MCOLN2	2.44e-04	114	50	4	PF00520
Domain	MIR	RYR1 RYR3	3.12e-04	10	50	2	PS50919
Domain	MIR	RYR1 RYR3	3.12e-04	10	50	2	PF02815
Domain	MIR	RYR1 RYR3	3.12e-04	10	50	2	SM00472
Domain	MIR_motif	RYR1 RYR3	3.12e-04	10	50	2	IPR016093
Domain	Pept_M10A_Zn_BS	MMP2 MMP20	7.21e-04	15	50	2	IPR021158
Domain	PG_binding_1	MMP2 MMP20	1.29e-03	20	50	2	PF01471
Domain	Peptidoglycan-bd-like	MMP2 MMP20	1.29e-03	20	50	2	IPR002477
Domain	Hemopexin-like_dom	MMP2 MMP20	1.71e-03	23	50	2	IPR000585
Domain	Hemopexin-like_repeat	MMP2 MMP20	1.71e-03	23	50	2	IPR018487
Domain	M10A_MMP	MMP2 MMP20	1.71e-03	23	50	2	IPR033739
Domain	Hemopexin	MMP2 MMP20	1.71e-03	23	50	2	PF00045
Domain	HEMOPEXIN	MMP2 MMP20	1.71e-03	23	50	2	PS00024
Domain	-	MMP2 MMP20	1.71e-03	23	50	2	2.110.10.10
Domain	HEMOPEXIN_2	MMP2 MMP20	1.71e-03	23	50	2	PS51642
Domain	HX	MMP2 MMP20	1.71e-03	23	50	2	SM00120
Domain	Pept_M10A	MMP2 MMP20	1.71e-03	23	50	2	IPR021190
Domain	Peptidase_M10	MMP2 MMP20	1.87e-03	24	50	2	PF00413
Domain	ZnMc	MMP2 MMP20	2.72e-03	29	50	2	SM00235
Domain	Peptidase_Metallo	MMP2 MMP20	2.72e-03	29	50	2	IPR006026
Domain	Serpin_CS	SERPINC1 SERPINA9	3.31e-03	32	50	2	IPR023795
Domain	-	NSUN4 NDUFAF5 NTMT1	4.07e-03	120	50	3	3.40.50.150
Domain	Serpin_dom	SERPINC1 SERPINA9	4.18e-03	36	50	2	IPR023796
Domain	SAM-dependent_MTases	NSUN4 NDUFAF5 NTMT1	4.26e-03	122	50	3	IPR029063
Domain	SERPIN	SERPINC1 SERPINA9	4.41e-03	37	50	2	SM00093
Domain	SERPIN	SERPINC1 SERPINA9	4.41e-03	37	50	2	PS00284
Domain	Serpin	SERPINC1 SERPINA9	4.64e-03	38	50	2	PF00079
Domain	Serpin_fam	SERPINC1 SERPINA9	4.89e-03	39	50	2	IPR000215
Domain	CYSTEINE_SWITCH	MMP2 MMP20	5.39e-03	41	50	2	PS00546
Domain	Pept_M10_metallopeptidase	MMP2 MMP20	5.91e-03	43	50	2	IPR001818
Pubmed	Cdc2 and Cdk2 play critical roles in low dose doxorubicin-induced cell death through mitotic catastrophe but not in high dose doxorubicin-induced apoptosis.	CDK1 CDK2	2.19e-06	2	52	2	16036217
Pubmed	Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases.	CDK1 CDK2	2.19e-06	2	52	2	25541464
Pubmed	Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality.	CDK1 CDK2	2.19e-06	2	52	2	27831832
Pubmed	Differentiation of trophoblast stem cells into giant cells is triggered by p57/Kip2 inhibition of CDK1 activity.	CDK1 CDK2	2.19e-06	2	52	2	18981479
Pubmed	SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition.	CDK1 CDK2	2.19e-06	2	52	2	20062077
Pubmed	Genetic substitution of Cdk1 by Cdk2 leads to embryonic lethality and loss of meiotic function of Cdk2.	CDK1 CDK2	2.19e-06	2	52	2	18787066
Pubmed	Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein.	CDK1 CDK2	2.19e-06	2	52	2	7716549
Pubmed	Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene.	RYR1 RYR3	2.19e-06	2	52	2	12565913
Pubmed	Contractile impairment and structural alterations of skeletal muscles from knockout mice lacking type 1 and type 3 ryanodine receptors.	RYR1 RYR3	2.19e-06	2	52	2	9489997
Pubmed	Functional and morphological features of skeletal muscle from mutant mice lacking both type 1 and type 3 ryanodine receptors.	RYR1 RYR3	2.19e-06	2	52	2	9192302
Pubmed	The block of ryanodine receptors selectively inhibits fetal myoblast differentiation.	RYR1 RYR3	2.19e-06	2	52	2	12640042
Pubmed	Nuclear pore formation but not nuclear growth is governed by cyclin-dependent kinases (Cdks) during interphase.	CDK1 CDK2	2.19e-06	2	52	2	20711190
Pubmed	A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts.	ACP5 PLEKHM1	2.19e-06	2	52	2	17997709
Pubmed	Residual Cdk1/2 activity after DNA damage promotes senescence.	CDK1 CDK2	2.19e-06	2	52	2	28345297
Pubmed	Isolation and partial cloning of ryanodine-sensitive Ca2+ release channel protein isoforms from human myometrial smooth muscle.	RYR1 RYR3	2.19e-06	2	52	2	7556644
Pubmed	Dicer ablation promotes a mesenchymal and invasive phenotype in bladder cancer cells.	MMP2 DICER1	2.19e-06	2	52	2	26166215
Pubmed	Cdk1, but not Cdk2, is the sole Cdk that is essential and sufficient to drive resumption of meiosis in mouse oocytes.	CDK1 CDK2	2.19e-06	2	52	2	22367880
Pubmed	Possible involvement of ryanodine receptor-mediated intracellular calcium release in the effect of corticotropin-releasing factor on adrenocorticotropin secretion.	RYR1 RYR3	2.19e-06	2	52	2	14592949
Pubmed	Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells.	CDK1 CDK2	2.19e-06	2	52	2	19061641
Pubmed	The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.	CDK1 CDK2	2.19e-06	2	52	2	25218592
Pubmed	Ryanodine receptors in muscarinic receptor-mediated bronchoconstriction.	RYR1 RYR3	2.19e-06	2	52	2	15894801
Pubmed	Morphological abnormalities of adrenal gland and hypertrophy of liver in mutant mice lacking ryanodine receptors.	RYR1 RYR3	2.19e-06	2	52	2	9799464
Pubmed	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.	CDK1 CDK2	2.19e-06	2	52	2	19239702
Pubmed	Key role for cyclin-dependent kinases in the first and second meiotic divisions of rat spermatocytes.	CDK1 CDK2	2.19e-06	2	52	2	14695906
Pubmed	Effect of calmodulin on Ca2+-induced Ca2+ release of skeletal muscle from mutant mice expressing either ryanodine receptor type 1 or type 3.	RYR1 RYR3	2.19e-06	2	52	2	9817784
Pubmed	Cell cycle sibling rivalry: Cdc2 vs. Cdk2.	CDK1 CDK2	2.19e-06	2	52	2	16258277
Pubmed	Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?	CDK1 CDK2	2.19e-06	2	52	2	19723060
Pubmed	CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence.	CDK1 CDK2	2.19e-06	2	52	2	25443276
Pubmed	Expression and functional activity of ryanodine receptors (RyRs) during skeletal muscle development.	RYR1 RYR3	2.19e-06	2	52	2	17118445
Pubmed	RyR3 amplifies RyR1-mediated Ca(2+)-induced Ca(2+) release in neonatal mammalian skeletal muscle.	RYR1 RYR3	2.19e-06	2	52	2	11500519
Pubmed	Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase.	CDK1 CDK2	2.19e-06	2	52	2	9882337
Pubmed	Type 1 and type 3 ryanodine receptors are selectively involved in muscarinic antinociception in mice: an antisense study.	RYR1 RYR3	6.57e-06	3	52	2	18403125
Pubmed	Characterization and mapping of the 12 kDa FK506-binding protein (FKBP12)-binding site on different isoforms of the ryanodine receptor and of the inositol 1,4,5-trisphosphate receptor.	RYR1 RYR3	6.57e-06	3	52	2	11171121
Pubmed	Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division.	CDK1 CDK2	6.57e-06	3	52	2	35115540
Pubmed	Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2.	CDK1 CDK2	6.57e-06	3	52	2	20935635
Pubmed	Differential alterations in expressions of ryanodine receptor subtypes in cerebellar cortical neurons of an ataxic mutant, rolling mouse Nagoya.	RYR1 RYR3	6.57e-06	3	52	2	18313230
Pubmed	Heterogeneous gene expression and functional activity of ryanodine receptors in resistance and conduit pulmonary as well as mesenteric artery smooth muscle cells.	RYR1 RYR3	6.57e-06	3	52	2	18434746
Pubmed	Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression.	CDK1 CDK2	6.57e-06	3	52	2	25071185
Pubmed	Cyclin A1 is required for meiosis in the male mouse.	CDK1 CDK2	6.57e-06	3	52	2	9843212
Pubmed	Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints.	CDK1 CDK2	6.57e-06	3	52	2	12912980
Pubmed	Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.	CDK1 CDK2	6.57e-06	3	52	2	1388288
Pubmed	SPRY domains in ryanodine receptors (Ca(2+)-release channels).	RYR1 RYR3	6.57e-06	3	52	2	9204703
Pubmed	The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues.	RYR1 RYR3	6.57e-06	3	52	2	7876312
Pubmed	WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.	CDK1 CDK2	6.57e-06	3	52	2	32120135
Pubmed	Requirement of Cyclin/Cdk2 and protein phosphatase 1 activity for chromatin assembly factor 1-dependent chromatin assembly during DNA synthesis.	CDK1 CDK2	6.57e-06	3	52	2	10938080
Pubmed	Ryanodine receptors are expressed in epidermal keratinocytes and associated with keratinocyte differentiation and epidermal permeability barrier homeostasis.	RYR1 RYR3	6.57e-06	3	52	2	21881589
Pubmed	Cyclin A is required at two points in the human cell cycle.	CDK1 CDK2	6.57e-06	3	52	2	1312467
Pubmed	p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint.	CDK1 CDK2	6.57e-06	3	52	2	17942597
Pubmed	Differential regulation of CDP/Cux p110 by cyclin A/Cdk2 and cyclin A/Cdk1.	CDK1 CDK2	6.57e-06	3	52	2	16081423
Pubmed	KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases.	CDK1 CDK2	6.57e-06	3	52	2	8127873
Pubmed	Isoform-dependent formation of heteromeric Ca2+ release channels (ryanodine receptors).	RYR1 RYR3	6.57e-06	3	52	2	12213830
Pubmed	Evaluation of genetic polymorphisms in MMP2, MMP9 and MMP20 in Brazilian children with dental fluorosis.	MMP2 MMP20	6.57e-06	3	52	2	30639979
Pubmed	Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress.	CDK1 CDK2	6.57e-06	3	52	2	25616574
Pubmed	Matrix metalloproteinase inhibition impairs the processing, formation and mineralization of dental tissues during mouse molar development.	MMP2 MMP20	6.57e-06	3	52	2	15748894
Pubmed	Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells.	RYR1 RYR3	6.57e-06	3	52	2	9242641
Pubmed	Bidirectional coupling between ryanodine receptors and Ca2+ release-activated Ca2+ (CRAC) channel machinery sustains store-operated Ca2+ entry in human T lymphocytes.	RYR1 RYR3	6.57e-06	3	52	2	22948152
Pubmed	Developmental changes in expression of the three ryanodine receptor mRNAs in the mouse brain.	RYR1 RYR3	6.57e-06	3	52	2	10788707
Pubmed	Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.	MMP2 CDK2	6.57e-06	3	52	2	30842588
Pubmed	Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication.	CDK1 CDK2	6.57e-06	3	52	2	11278991
Pubmed	Calcineurin upregulates local Ca(2+) signaling through ryanodine receptor-1 in airway smooth muscle cells.	RYR1 RYR3	6.57e-06	3	52	2	25239916
Pubmed	Ca(2+)-induced Ca2+ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor.	RYR1 RYR3	6.57e-06	3	52	2	7621815
Pubmed	A gene-specific cerebral types 1, 2, and 3 RyR protein knockdown induces an antidepressant-like effect in mice.	RYR1 RYR3	6.57e-06	3	52	2	18643873
Pubmed	Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2).	RYR1 RYR3	6.57e-06	3	52	2	11159936
Pubmed	Novel transglutaminase-like peptidase and C2 domains elucidate the structure, biogenesis and evolution of the ciliary compartment.	C2CD3 CC2D2B	6.57e-06	3	52	2	22983010
Pubmed	Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation.	CDK1 CDK2	6.57e-06	3	52	2	11953320
Pubmed	Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression.	CDK1 CDK2	6.57e-06	3	52	2	10767298
Pubmed	On the concentrations of cyclins and cyclin-dependent kinases in extracts of cultured human cells.	CDK1 CDK2	6.57e-06	3	52	2	10924145
Pubmed	CDK phosphorylation of the discs large tumour suppressor controls its localisation and stability.	CDK1 CDK2	6.57e-06	3	52	2	19066288
Pubmed	[Expression of MMP-2 and MMP-9 in the tartrate-resistant acid phosphatase (TRAP)-positive mononuclear and multinucleated cells is correlated with articular cartilage damage].	ACP5 MMP2	6.57e-06	3	52	2	15862156
Pubmed	Molecular identification of the ryanodine receptor pore-forming segment.	RYR1 RYR3	6.57e-06	3	52	2	10473538
Pubmed	Inhibition of human cytomegalovirus immediate-early gene expression by cyclin A2-dependent kinase activity.	CDK1 CDK2	6.57e-06	3	52	2	22718829
Pubmed	Chromosomal localization of murine ryanodine receptor genes RYR1, RYR2, and RYR3 by in situ hybridization.	RYR1 RYR3	6.57e-06	3	52	2	7959768
Pubmed	The organization of proteins in the human red blood cell membrane. A review.	RYR1 RYR3	6.57e-06	3	52	2	4600883
Pubmed	Regulation of mouse egg activation: presence of ryanodine receptors and effects of microinjected ryanodine and cyclic ADP ribose on uninseminated and inseminated eggs.	RYR1 RYR3	6.57e-06	3	52	2	7635066
Pubmed	Characterization of the binding sites for the interactions between FKBP12 and intracellular calcium release channels.	RYR1 RYR3	1.31e-05	4	52	2	22100703
Pubmed	Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe.	CDK1 CDK2	1.31e-05	4	52	2	2227411
Pubmed	SET-related cell division autoantigen-1 (CDA1) arrests cell growth.	CDK1 CDK2	1.31e-05	4	52	2	11395479
Pubmed	A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons.	RYR1 RYR3	1.31e-05	4	52	2	18206662
Pubmed	Phosphorylation of minichromosome maintenance protein 7 (MCM7) by cyclin/cyclin-dependent kinase affects its function in cell cycle regulation.	CDK1 CDK2	1.31e-05	4	52	2	23720738
Pubmed	Cyclin B and cyclin A confer different substrate recognition properties on CDK2.	CDK1 CDK2	1.31e-05	4	52	2	17495531
Pubmed	Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells.	CDK1 CDK2	1.31e-05	4	52	2	9467962
Pubmed	p110δ phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression.	PIK3CG BCL6	1.31e-05	4	52	2	22422878
Pubmed	Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin.	CDK1 CDK2	1.31e-05	4	52	2	11069302
Pubmed	Phosphorylation of replication protein A middle subunit (RPA32) leads to a disassembly of the RPA heterotrimer.	CDK1 CDK2	1.31e-05	4	52	2	10336450
Pubmed	Functional reprogramming of polyploidization in megakaryocytes.	CDK1 CDK2	1.31e-05	4	52	2	25625205
Pubmed	Phosphorylation of human DNA polymerase lambda by the cyclin-dependent kinase Cdk2/cyclin A complex is modulated by its association with proliferating cell nuclear antigen.	CDK1 CDK2	1.31e-05	4	52	2	16174846
Pubmed	Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.	CDK1 CDK2	1.31e-05	4	52	2	17386261
Pubmed	Ryanodine receptor calcium release channels: lessons from structure-function studies.	RYR1 RYR3	1.31e-05	4	52	2	23413940
Pubmed	Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2.	CDK1 CDK2	1.31e-05	4	52	2	8242750
Pubmed	Nuclear phosphoproteomics analysis reveals that CDK1/2 are involved in EGF-regulated constitutive pre-mRNA splicing in MDA-MB-468 cells.	CDK1 CDK2	1.31e-05	4	52	2	27109354
Pubmed	A kinase associated with chromatin that can be activated by ligand-p185c-Neu or epidermal growth factor-receptor interactions.	CDK1 CDK2	1.31e-05	4	52	2	7604037
Pubmed	Site-specific phosphorylation of MCM4 during the cell cycle in mammalian cells.	CDK1 CDK2	1.31e-05	4	52	2	16519687
Pubmed	Requirement for the ryanodine receptor type 3 for efficient contraction in neonatal skeletal muscles.	RYR1 RYR3	1.31e-05	4	52	2	9384575
Pubmed	A Putative Cyclin-binding Motif in Human SAMHD1 Contributes to Protein Phosphorylation, Localization, and Stability.	CDK1 CDK2	1.31e-05	4	52	2	27815502
Pubmed	A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein.	CDK1 CDK2	1.31e-05	4	52	2	11306463
Pubmed	CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.	CDK1 CDK2	1.31e-05	4	52	2	23776131
Pubmed	Partial cloning and differential expression of ryanodine receptor/calcium-release channel genes in human tissues including the hippocampus and cerebellum.	RYR1 RYR3	1.31e-05	4	52	2	9607712
Pubmed	Identification of a novel vertebrate cyclin: cyclin B3 shares properties with both A- and B-type cyclins.	CDK1 CDK2	1.31e-05	4	52	2	8313904
Pubmed	New role of human ribosomal protein S3: Regulation of cell cycle via phosphorylation by cyclin-dependent kinase 2.	CDK1 CDK2	1.31e-05	4	52	2	28521470
Pubmed	NF-Y binds to both G1- and G2-specific cyclin promoters; a possible role in linking CDK2/Cyclin A to CDK1/Cyclin B.	CDK1 CDK2	1.31e-05	4	52	2	21871181
Cytoband	14q32.13	DICER1 SERPINA9	1.69e-04	17	52	2	14q32.13
Cytoband	20p12.3	FERMT1 GPCPD1	1.90e-04	18	52	2	20p12.3
Cytoband	Ensembl 112 genes in cytogenetic band chr20p12	NDUFAF5 FERMT1 GPCPD1	3.51e-04	120	52	3	chr20p12
GeneFamily	Ryanodine receptors\|Protein phosphatase 1 regulatory subunits	RYR1 RYR3	1.36e-05	3	39	2	287
GeneFamily	Endogenous ligands\|Matrix metallopeptidases	MMP2 MMP20	1.21e-03	24	39	2	891
GeneFamily	Cyclin dependent kinases	CDK1 CDK2	1.43e-03	26	39	2	496
GeneFamily	Serpin peptidase inhibitors	SERPINC1 SERPINA9	2.88e-03	37	39	2	739
CoexpressionAtlas	CD positive, CD4 Control, 4+8-B220-, Spleen, avg-2	TNIK THEMIS ST8SIA6 TXK	9.20e-06	55	51	4	GSM403994_100
CoexpressionAtlas	CD positive, CD4 Control, 4+ 8- B220-, Spleen, avg-4	TNIK THEMIS ST8SIA6 NXPE3 TXK	1.46e-04	210	51	5	GSM403995_500
CoexpressionAtlas	alpha beta T cells, T.4.PLN.BDC, 4+ 8- BDC+, Lymph Node, avg-3	TNIK THEMIS ST8SIA6 ACP5 NXPE3 TXK	1.48e-04	336	51	6	GSM605758_500
CoexpressionAtlas	alpha beta T cells, T.4.TI.B16, 4+ 8- TCR+ 45+, B16 Melanoma Tumor, avg-3	TNIK THEMIS ST8SIA6 ACP5 NXPE3 TXK	1.53e-04	338	51	6	GSM605763_500
CoexpressionAtlas	alpha beta T cells, T.4Nve.Sp, 4+ 8- 25- 62Lhi 44lo, Spleen, avg-4	TNIK THEMIS ST8SIA6 ACP5 NXPE3 TXK	1.56e-04	339	51	6	GSM538382_500
CoexpressionAtlas	alpha beta T cells, T.4Nve.MLN, 4+ 8- 25- 62Lhi 44lo, Lymph Node, avg-3	TNIK THEMIS ST8SIA6 ACP5 NXPE3 TXK	1.69e-04	344	51	6	GSM538377_500
CoexpressionAtlas	alpha beta T cells, T.4FP3+25+.Sp, 4+ 8- GFP+ 25+, Spleen, avg-3	TNIK THEMIS ST8SIA6 GBP2 NXPE3 TXK	1.69e-04	344	51	6	GSM399365_500
CoexpressionAtlas	alpha beta T cells, T.4Mem.LN, TCRb CD44high CD122lo CD4, Lymph Node, avg-3	TNIK THEMIS ST8SIA6 BCL6 NXPE3 TXK	1.80e-04	348	51	6	GSM538362_500
CoexpressionAtlas	gamma delta T cells, Tgd.Th, TCRd+ CD3e+, Thymus, avg-3	TNIK THEMIS ATAD5 GYG1 CDK1 TXK	1.82e-04	349	51	6	GSM476675_500
CoexpressionAtlas	CD positive, CD4 Control, 4+ 8- B220-, Spleen, avg-4	THEMIS ST8SIA6 TXK	1.96e-04	47	51	3	GSM403995_100
CoexpressionAtlas	alpha beta T cells, T.4.LN.BDC, 4+ 8- BDC+, Lymph Node, avg-3	TNIK THEMIS ST8SIA6 ACP5 NXPE3 TXK	1.97e-04	354	51	6	GSM605753_500
CoexpressionAtlas	CD positive, CD4 Control, 4+8-B220-, Spleen, avg-2	TNIK THEMIS ST8SIA6 NXPE3 TXK	1.98e-04	224	51	5	GSM403994_500
CoexpressionAtlas	CD positive, CD4 Test NA, 4+8-B220-, Spleen, avg-1	TNIK THEMIS ST8SIA6 ACP5 NXPE3 TXK	2.06e-04	357	51	6	GSM403986_500
CoexpressionAtlas	CD positive, CD4 Test JS, 4+8-B220-, Spleen, avg-3	TNIK THEMIS ST8SIA6 ACP5 NXPE3 TXK	2.12e-04	359	51	6	GSM404000_500
CoexpressionAtlas	alpha beta T cells, T.4FP3-.Sp, 4+ 8- GFP- 44lo, Spleen, avg-3	TNIK THEMIS ST8SIA6 ACP5 NXPE3 TXK	2.29e-04	364	51	6	GSM605766_500
CoexpressionAtlas	alpha beta T cells, T.8Mem.Sp.OT1.d106.VSVOva, CD8+ CD45.1+, Spleen, avg-2	TNIK THEMIS ACP5 USP48 MCOLN2 TXK	2.39e-04	367	51	6	GSM538401_500
CoexpressionAtlas	alpha beta T cells, T.4Nve.LN, 4+ 8- 25- 62Lhi 44lo, Lymph Node, avg-3	THEMIS ST8SIA6 TXK	2.51e-04	51	51	3	GSM538374_100
CoexpressionAtlas	gamma delta T cells, Tgd.vg1+vd6-.Th, TCRd+ Vg1.1+, Thymus, avg-3	TNIK THEMIS ATAD5 GYG1 CDK1 TXK	2.61e-04	373	51	6	GSM605781_500
CoexpressionAtlas	alpha beta T cells, T.4Nve.MLN, 4+ 8- 25- 62Lhi 44lo, Lymph Node, avg-3	THEMIS ST8SIA6 TXK	2.65e-04	52	51	3	GSM538377_100
CoexpressionAtlas	alpha beta T cells, T.8SP24int.Th, 4- 8+ TCRhi 24int, Thymus, avg-3	TNIK THEMIS TXK	2.65e-04	52	51	3	GSM399382_100
CoexpressionAtlas	alpha beta T cells, T.4Nve.PP, TCR+ CD4+ CD44low CD62Lhigh, Peyer's Patch, avg-2	THEMIS ST8SIA6 TXK	2.81e-04	53	51	3	GSM538380_100
CoexpressionAtlas	alpha beta T cells, T.4Nve.Sp, 4+ 8- 25- 62Lhi 44lo, Spleen, avg-4	THEMIS ST8SIA6 TXK	2.97e-04	54	51	3	GSM538382_100
CoexpressionAtlas	alpha beta T cells, T.4int8+.Th, 4int 8+ TCRhi, Thymus, avg-3	TNIK THEMIS TXK	2.97e-04	54	51	3	GSM399367_100
CoexpressionAtlas	alpha beta T cells, T.8Mem.Sp.OT1.d45.LisOva, CD8+ CD45.1+, Spleen, avg-2	TNIK THEMIS ACP5 USP48 MCOLN2 TXK	3.01e-04	383	51	6	GSM605907_500
CoexpressionAtlas	alpha beta T cells, T.8Mem.Sp.OT1.d45.VSVOva, CD8+ CD45.1+, Spleen, avg-3	TNIK THEMIS ACP5 USP48 MCOLN2 TXK	3.01e-04	383	51	6	GSM538403_500
CoexpressionAtlas	DevelopingKidney_e15.5_Ureteral Smooth Musc_emap-28812_k-means-cluster#5_top-relative-expression-ranked_200	RYR3 NXPE3	3.07e-04	11	51	2	gudmap_developingKidney_e15.5_Ureteral Smooth Musc_200_k5
CoexpressionAtlas	CD positive, CD4 Test CJ, 4+8-B220-, Spleen, avg-2	THEMIS ST8SIA6 TXK	3.14e-04	55	51	3	GSM404003_100
CoexpressionAtlas	CD positive, CD4 Test NA, 4+8-B220-, Spleen, avg-1	THEMIS ST8SIA6 TXK	3.31e-04	56	51	3	GSM403986_100
CoexpressionAtlas	alpha beta T cells, T.4+8int.Th, 4+ 8int TCRhi, Thymus, avg-3	TNIK THEMIS TXK	3.31e-04	56	51	3	GSM399362_100
CoexpressionAtlas	alpha beta T cells, T.4.TI.B16, 4+ 8- TCR+ 45+, B16 Melanoma Tumor, avg-3	THEMIS ST8SIA6 TXK	3.49e-04	57	51	3	GSM605763_100
CoexpressionAtlas	CD positive, CD4 Test DB, 4+8-B220-, Spleen, avg-1	THEMIS ST8SIA6 TXK	3.67e-04	58	51	3	GSM403987_100
CoexpressionAtlas	alpha beta T cells, T.8SP69+.Th, 4- 8+ TCRhi 69+, Thymus, avg-3	TNIK THEMIS TXK	3.67e-04	58	51	3	GSM399385_100
CoexpressionAtlas	alpha beta T cells, NKT.44-NK1.1-.Th, aGC CD1d tet CD3e, Thymus, avg-2	TNIK THEMIS ST8SIA6 ATAD5 CDK1 TXK	3.69e-04	398	51	6	GSM538338_500
CoexpressionAtlas	alpha beta T cells, T.4SP69+.Th, 4+ 8- TCRhi 69+, Thymus, avg-3	TNIK THEMIS TXK	3.86e-04	59	51	3	GSM399376_100
CoexpressionAtlas	alpha beta T cells, T.4FP3-.Sp, 4+ 8- GFP- 44lo, Spleen, avg-3	THEMIS ST8SIA6 TXK	3.86e-04	59	51	3	GSM605766_100
CoexpressionAtlas	alpha beta T cells, T.4SP24int.Th, 4+ 8- TCRhi 24int, Thymus, avg-3	TNIK THEMIS TXK	4.06e-04	60	51	3	GSM399373_100
CoexpressionAtlas	CD positive, CD4 Test JS, 4+8-B220-, Spleen, avg-3	THEMIS ST8SIA6 TXK	4.26e-04	61	51	3	GSM404000_100
CoexpressionAtlas	gamma delta T cells, Tgd.vg2+24ahi.e17.Th, TCRd+ Vg2+ CD24+, Fetal Thymus, avg-3	TNIK THEMIS ATAD5 GYG1 CDK1 TXK	4.54e-04	414	51	6	GSM476660_500
CoexpressionAtlas	CD positive, CD4 Test CJ, 4+8-B220-, Spleen, avg-2	TNIK THEMIS ST8SIA6 NXPE3 TXK	5.50e-04	280	51	5	GSM404003_500
CoexpressionAtlas	alpha beta T cells, T.8Nve.PP, TCRb+ CD8+ CD44low CD62Lhigh, Peyer's Patch, avg-1	TNIK THEMIS TXK	5.61e-04	67	51	3	GSM538414_100
CoexpressionAtlas	alpha beta T cells, T.8Nve.PP, TCRb+ CD8+ CD44low CD62L high, Peyer's Patch, avg-1	TNIK THEMIS TXK	6.12e-04	69	51	3	GSM538413_100
CoexpressionAtlas	alpha beta T cells, T.8Nve.PP, TCR+ CD8+ CD44low CD62Lhigh, Peyer's Patch, avg-1	TNIK THEMIS TXK	6.12e-04	69	51	3	GSM538412_100
CoexpressionAtlas	gamma delta T cells, Tgd.vg2+.Sp, TCRd+ Vg2+ CD44-, Spleen, avg-3	TNIK THEMIS TXK	6.93e-04	72	51	3	GSM605787_100
CoexpressionAtlas	alpha beta T cells, T.8Nve.PP, TCRb+ CD8+ CD44low CD62Lhigh, Peyer's Patch, avg-1	TNIK THEMIS TENM4 ACP5 TXK	7.18e-04	297	51	5	GSM538414_500
CoexpressionAtlas	alpha beta T cells, T.8Mem.Sp, 4- 8+ 25- 44hi 122hi, Spleen, avg-3	TNIK THEMIS ACP5 MCOLN2 TXK	7.86e-04	303	51	5	GSM538398_500
CoexpressionAtlas	alpha beta T cells, T.DP69+.Th, 4+ 8+ TCRlo/int 69+, Thymus, avg-3	TNIK THEMIS BCL6 DMWD TXK	8.09e-04	305	51	5	GSM399394_500
CoexpressionAtlas	alpha beta T cells, T.4.Pa.BDC, 4+ 8- BDC+, Pancreas, avg-2	TNIK THEMIS TXK	8.75e-04	78	51	3	GSM605756_100
CoexpressionAtlas	gamma delta T cells, Tgd.vg2-.Sp, TCRd+ Vg2- CD44-, Spleen, avg-3	TNIK THEMIS TXK	9.08e-04	79	51	3	GSM476684_100
CoexpressionAtlas	alpha beta T cells, T.4Nve.PP, TCR+ CD4+ CD44low CD62Lhigh, Peyer's Patch, avg-2	TNIK THEMIS ST8SIA6 NXPE3 TXK	1.10e-03	327	51	5	GSM538380_500
CoexpressionAtlas	alpha beta T cells, T.4.Pa.BDC, 4+ 8- BDC+, Pancreas, avg-2	TNIK THEMIS ST8SIA6 BCL6 TXK	1.12e-03	328	51	5	GSM605756_500
CoexpressionAtlas	gamma delta T cells, Tgd.vg3+24alo.e17.Th, TCRd+ Vg3+ CD24-, Fetal Thymus, avg-3	THEMIS CDK1 TXK	1.12e-03	85	51	3	GSM476664_100
CoexpressionAtlas	alpha beta T cells, T.8.Sp.B16, 4- 8+ TCR+ 45+, B16 Melanoma Spleen, avg-3	TNIK THEMIS ACP5 MCOLN2 TXK	1.23e-03	335	51	5	GSM605770_500
CoexpressionAtlas	alpha beta T cells, T.4Nve.LN, 4+ 8- 25- 62Lhi 44lo, Lymph Node, avg-3	TNIK THEMIS ST8SIA6 NXPE3 TXK	1.25e-03	336	51	5	GSM538374_500
CoexpressionAtlas	CD positive, CD4 Test DB, 4+8-B220-, Spleen, avg-1	TNIK THEMIS ST8SIA6 NXPE3 TXK	1.28e-03	338	51	5	GSM403987_500
CoexpressionAtlas	alpha beta T cells, NKT.44-NK1.1-.Th, aGC CD1d tet CD3e, Thymus, avg-2	THEMIS ST8SIA6 TXK	1.32e-03	90	51	3	GSM538338_100
CoexpressionAtlas	alpha beta T cells, T.4Mem.Sp, 4+ 8- 25- 44hi 122lo, Spleen, avg-3	TNIK THEMIS ST8SIA6 NXPE3 TXK	1.36e-03	343	51	5	GSM538365_500
CoexpressionAtlas	alpha beta T cells, T.4Mem44h62l.LN, CD4 TCRb CD44hi CD62Llo, Lymph Node, avg-3	TNIK THEMIS BCL6 NXPE3 TXK	1.42e-03	346	51	5	GSM538368_500
CoexpressionAtlas	alpha beta T cells, T.8SP24-.Th, 4- 8+ TCRhi 24-/lo, Thymus, avg-3	TNIK THEMIS ACP5 CDK1 TXK	1.51e-03	351	51	5	GSM399379_500
CoexpressionAtlas	CD positive, T.8Nve.Sp.OT1, CD8+ CD45.1+, Spleen, avg-3	TNIK THEMIS ACP5 MCOLN2 TXK	1.65e-03	358	51	5	GSM605909_500
CoexpressionAtlas	alpha beta T cells, T.8Eff.Sp.OT1.d15.VSVOva, CD8+ CD45.1+, Spleen, avg-2	TNIK THEMIS ACP5 USP48 TXK	1.71e-03	361	51	5	GSM538385_500
CoexpressionAtlas	alpha beta T cells, T.8Mem.Sp.OT1.d100.LisOva, CD8+ CD45.1+, Spleen, avg-3	TNIK THEMIS ACP5 MCOLN2 TXK	1.79e-03	365	51	5	GSM605904_500
CoexpressionAtlas	alpha beta T cells, T.4SP24-.Th, 4+ 8- TCRhi 24-/lo, Thymus, avg-3	TNIK THEMIS ST8SIA6 NXPE3 TXK	1.79e-03	365	51	5	GSM399370_500
CoexpressionAtlas	alpha beta T cells, T.8Eff.Sp.OT1.d10.LisOva, CD8+ CD45.1+, Spleen, avg-3	TNIK THEMIS ACP5 USP48 TXK	1.88e-03	369	51	5	GSM605891_500
CoexpressionAtlas	DevelopingGonad_e16.5_ovary_emap-9563_k-means-cluster#5_top-relative-expression-ranked_1000	TNIK CPEB4 LRRTM4 RYR1	1.88e-03	219	51	4	gudmap_developingGonad_e16.5_ovary_1000_k5
CoexpressionAtlas	alpha beta T cells, T.8Eff.Sp.OT1.d15.LisOva, CD8+ CD45.1+, Spleen, avg-3	TNIK THEMIS ACP5 USP48 TXK	2.04e-03	376	51	5	GSM605894_500
CoexpressionAtlas	alpha beta T cells, T.8Eff.Sp.OT1.d8.LisOva, CD8+ CD45.1+, Spleen, avg-3	TNIK THEMIS ACP5 USP48 TXK	2.14e-03	380	51	5	GSM605901_500
CoexpressionAtlas	gamma delta T cells, Tgd.vg2-.Sp, TCRd+ Vg2- CD44-, Spleen, avg-3	TNIK THEMIS ACP5 MCOLN2 TXK	2.19e-03	382	51	5	GSM476684_500
ToppCell	Children_(3_yrs)-Immune-mast_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TNIK TDRD15 ST8SIA6 FERMT1 RYR3	9.12e-07	151	52	5	bbf735c6433c3fc2feedb24ed6f48c51d545fb60
ToppCell	Children_(3_yrs)-Immune-mast_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TNIK TDRD15 ST8SIA6 FERMT1 RYR3	1.11e-06	157	52	5	ec185dbeabb67fd9ca85f71cab88463b60f9b1c1
ToppCell	Immune-mast_cell\|World / Lineage, Cell type, age group and donor	TNIK TDRD15 ST8SIA6 FERMT1 RYR3	1.73e-06	172	52	5	6e8e0aac5a20dbc789bf8c6916833bb8709a411a
ToppCell	droplet-Marrow-nan-24m-Hematologic-erythroid_progenitor\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ST8SIA6 GBP2 SERPINC1 RYR1 MCOLN2	1.73e-06	172	52	5	910ec7794ea4000db4ef1e2c34e08dbc0243df2c
ToppCell	droplet-Lung-LUNG-1m-Lymphocytic-Zbtb32+_B\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TENM4 ST8SIA6 ACP5 GPCPD1 MCOLN2	2.05e-06	178	52	5	9b932b677ae05ac6e12cd6ce97789f8c10e4790b
ToppCell	COVID-19_Convalescent-Classical_Monocyte-cMono_4\|Classical_Monocyte / Disease condition and Cell class	ATAD5 ACO1 ZFYVE19 DHX57 ERI1	2.11e-06	179	52	5	9d51318ac198a8801bd5c7031ebf2b0c74ffeeb6
ToppCell	COVID-19_Convalescent-Classical_Monocyte-cMono_4\|COVID-19_Convalescent / Disease condition and Cell class	ATAD5 ACO1 ZFYVE19 DHX57 ERI1	2.11e-06	179	52	5	366e4a31db9e80fd1770ac9f1ae148fefeb9f7df
ToppCell	343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0.5\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	THEMIS NDUFAF5 GPCPD1 MCOLN2 NXPE3	2.28e-06	182	52	5	c98da2db197b1531204e116600ff51891e5c17af
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_Arw_fibro_(16)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	TNIK PRDM8 TENM4 MMP2 RYR3	2.61e-06	187	52	5	5258674d0346e5c51a4b965efcdc1790c970845d
ToppCell	Children_(3_yrs)-Immune-mast_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TNIK ST8SIA6 FERMT1 RYR3	2.55e-05	146	52	4	f7349d63bb47f1f22ced8ff514edc1c11bc782e7
ToppCell	Children_(3_yrs)-Immune-dendritic_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TENM4 PIK3CG BCL6 MCOLN2	2.99e-05	152	52	4	0769857f25da2e6169420818e61d65e33b7277b1
ToppCell	COVID-19-Mast_cells-Mast_cells\|COVID-19 / group, cell type (main and fine annotations)	TNIK ST8SIA6 FERMT1 RYR3	3.31e-05	156	52	4	bc10b94673184ef384c6665b16a1209a8975a4f1
ToppCell	COVID-19-Mast_cells\|COVID-19 / group, cell type (main and fine annotations)	TNIK ST8SIA6 FERMT1 RYR3	3.31e-05	156	52	4	159504d43421ee83b9ab484816333ae549c9c2fd
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_B-Plasma_Cell-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TDRD15 PIK3CG KLHDC8A CPEB4	3.48e-05	158	52	4	6b51e5ee08e23924f5edbaf0a845a9232fb7ff7a
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_B-Plasma_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TDRD15 PIK3CG KLHDC8A CPEB4	3.48e-05	158	52	4	8dd83a2a4c2ec9cdc3a03df8b51ee22bee1c2888
ToppCell	facs-Lung-EPCAM-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNIK THEMIS ACP5 TXK	3.83e-05	162	52	4	b877b232f0a879a9058d81ad4730e7846484b7c3
ToppCell	facs-Lung-EPCAM-3m-Lymphocytic-CD4+_T\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNIK THEMIS ACP5 TXK	3.83e-05	162	52	4	7384a4dd38ed68ca02a72df6deff4d34c9694ce1
ToppCell	Immune_cells-T_cells\|World / Lineage and Cell class	TNIK THEMIS ACP5 TXK	3.93e-05	163	52	4	c5afdb5e7700bbd3ee8276910f9c4b4b3bcc3266
ToppCell	nucseq-Immune-Hematopoietic-Granulocytic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TNIK ST8SIA6 FERMT1 RYR3	4.12e-05	165	52	4	37615622c736e43260c38016e7c9e565ac97a3e8
ToppCell	nucseq-Immune-Hematopoietic-Granulocytic-Mast/Basophil\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TNIK ST8SIA6 FERMT1 RYR3	4.12e-05	165	52	4	640bb71e74a61df2fcb01ceeabe4c493ef836b21
ToppCell	nucseq-Immune-Hematopoietic\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TNIK ST8SIA6 FERMT1 RYR3	4.12e-05	165	52	4	f3df74b5763130c71c0a482a3a23f6b22acc2892
ToppCell	10x3'2.3-week_12-13-Lymphocytic_T-T_NK-Treg\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	PRDM8 THEMIS GBP2 TXK	4.42e-05	168	52	4	99117480687e2b8e7521d3ae9e020791757ec48e
ToppCell	E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	GYG1 MMP2 USP48 RYR3	4.52e-05	169	52	4	16c52a0f6d96ecc1832922fce9b39691849f0d73
ToppCell	Control-Mast_cells\|Control / group, cell type (main and fine annotations)	TNIK ST8SIA6 FERMT1 RYR3	4.52e-05	169	52	4	fdb9abca1d0f4fdc32dd8ac6231651ef34aa5afb
ToppCell	facs-Lung-24m-Hematologic-lymphocytic-CD8-positive,_alpha-beta_T_cell-CD8-positive,_alpha-beta_T_cell_l5\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	THEMIS RYR3 NXPE3 TXK	4.52e-05	169	52	4	a388e53deac861a185c31e9cceddae7bcb344700
ToppCell	droplet-Lung-21m-Hematologic-lymphocytic-CD8-positive,_alpha-beta_T_cell-CD8-positive,_alpha-beta_T_cell_l48\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ST8SIA6 DHX57 USP48 MCOLN2	4.62e-05	170	52	4	070d8683d1a5cc7d594ff0453c961a9bf982c2d0
ToppCell	Control-Mast_cells-Mast_cells\|Control / group, cell type (main and fine annotations)	TNIK ST8SIA6 FERMT1 RYR3	4.62e-05	170	52	4	c80f6d29096c372da95a8407f402349ff1bb7018
ToppCell	COVID-19-Heart-T_cell\|COVID-19 / Disease (COVID-19 only), tissue and cell type	THEMIS LRRTM4 RYR1 RYR3	4.73e-05	171	52	4	b2e753e811a7639956994609f73efcdb62d04f82
ToppCell	droplet-Lung-LUNG-30m-Lymphocytic-Zbtb32+_B\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TENM4 ST8SIA6 ACP5 SERPINC1	5.06e-05	174	52	4	28ec25767bbd4fd898738f9f4d2b585dc91b5adf
ToppCell	COVID-19-kidney-PCT-S3-2\|kidney / Disease (COVID-19 only), tissue and cell type	TDRD15 CYP3A43 SERPINC1 APOB	5.06e-05	174	52	4	5aa2fb631505600f37d2b87b02def7be139dc262
ToppCell	Control-B_cells-Plasma_cells\|Control / group, cell type (main and fine annotations)	PIK3CG CPEB4 USP48 NXPE3	5.18e-05	175	52	4	fb23858cfce71509cafbe0d9728e678012ff2962
ToppCell	COVID-19-kidney-PCT-S3-2\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TDRD15 CYP3A43 SERPINC1 APOB	5.29e-05	176	52	4	b6497324e3e52f514ce556a3fa0c3011c45dcc7b
ToppCell	facs-Marrow-T_cells-18m-Lymphocytic-BM_CD8_+_CD4_T_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNIK THEMIS ACP5 TXK	5.41e-05	177	52	4	6d86b2f97426b552dff5ce6ddf0ead1285ed618e
ToppCell	-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	IGKV1-8 CPEB4 SERPINA9 NXPE3	5.41e-05	177	52	4	ae2d2e138946535596fa30a55207f261cafda461
ToppCell	facs-Marrow-T_cells-18m-Lymphocytic-mature_alpha-beta_T_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TNIK THEMIS ACP5 TXK	5.41e-05	177	52	4	d8b1bbc224d062a57a6ad40b4b2af5d6e0fe63b3
ToppCell	facs-MAT-Fat-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ACP5 NXPE3 TXK	5.41e-05	177	52	4	b5c20c1247f11ebc97e9cb47482564cd74e36ca6
ToppCell	LA-17._Lymphocyte\|World / Chamber and Cluster_Paper	TDRD15 THEMIS PIK3CG TXK	5.53e-05	178	52	4	34ec499d03cc198cfefa19a724d4c81974052f65
ToppCell	facs-Lung-nan-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ST8SIA6 ACP5 TXK	5.53e-05	178	52	4	a9a8567d8fdc0fffd612fee16b5b29ef7b1c9307
ToppCell	Immune_cells-T_cells\|Immune_cells / Lineage and Cell class	TNIK THEMIS ACP5 TXK	5.53e-05	178	52	4	af420242277e2a4e2524002a2914b0538f79a134
ToppCell	facs-Lung-nan-3m-Lymphocytic-CD4+_T\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ST8SIA6 ACP5 TXK	5.53e-05	178	52	4	5ecbea15efd304057aef826ec2f385997bfaf0c9
ToppCell	343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0.5\|343B / Donor, Lineage, Cell class and subclass (all cells)	THEMIS NDUFAF5 MCOLN2 NXPE3	5.53e-05	178	52	4	ec6364432d37a32f5152d36d89f5e96dddb72a9d
ToppCell	T_cells-GZMK+_CD8+_T_cells\|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis	THEMIS GYG1 CDK1 MCOLN2	5.65e-05	179	52	4	798f208014f2229c597934775646ddbbacf94b69
ToppCell	facs-Lung-3m-Hematologic-lymphocytic-CD4-positive,_alpha-beta_T_cell-CD4-positive,_alpha-beta_T_cell_l5\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	THEMIS ST8SIA6 ACP5 TXK	5.77e-05	180	52	4	d6e69ac2bd619557ef62ada684c37a44dc4e3f41
ToppCell	CF-Myeloid-Alveolar_Macrophage\|CF / Disease state, Lineage and Cell class	TNIK DNASE2B ACO1 ACP5	5.77e-05	180	52	4	6a7c3a3f3a16ca9f109047adaf36f6a2746d6ab9
ToppCell	COPD-Myeloid-Mast\|World / Disease state, Lineage and Cell class	TNIK ST8SIA6 CPEB4 RYR3	6.03e-05	182	52	4	68a1e7b804f309bfd6c23d65fad20a9a962712ae
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c13-HAVCR2\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	TNIK PRDM8 ACP5 CDK1	6.03e-05	182	52	4	6c9a48037fa002bc528875538bdaaf15696d68b6
ToppCell	droplet-Lung-LUNG-1m-Lymphocytic-Proliferating_T\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ATAD5 SERPINC1 CDK1	6.16e-05	183	52	4	769a022fe8568ec49e66f792cc5777e713a7571c
ToppCell	facs-Lung-3m-Hematologic-lymphocytic-CD4-positive,_alpha-beta_T_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	THEMIS ST8SIA6 ACP5 TXK	6.16e-05	183	52	4	c9cb69377883d4579c608ec8b265153fe5290e67
ToppCell	droplet-Fat-BAT+GAT+MAT-30m-Lymphocytic-lymphocyte\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ACP5 NXPE3 TXK	6.16e-05	183	52	4	a305667cfdae50e64e1890f10f71b407ae617b80
ToppCell	droplet-Lung-LUNG-1m-Lymphocytic-T_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ATAD5 SERPINC1 CDK1	6.16e-05	183	52	4	aac0695fafa59cabd920ee18b1139d3e00d898e8
ToppCell	nucseq-Immune-Lymphocytic_B-Lymphocytic_B-Plasma\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	PIK3CG CPEB4 USP48 NXPE3	6.42e-05	185	52	4	3b77bc49cd3740acc025e162a36282ac09e12198
ToppCell	COPD-Myeloid-Mast\|COPD / Disease state, Lineage and Cell class	TNIK ST8SIA6 CPEB4 RYR3	6.56e-05	186	52	4	def6f0f284acc2154738574c8c5d3d2a5ef1f208
ToppCell	COVID-19-lung-Plasma_cells_PRDM1/BLIMP_hi\|lung / Disease (COVID-19 only), tissue and cell type	PIK3CG CPEB4 USP48 NXPE3	6.56e-05	186	52	4	66676d9395172de5707e204826a1c9f73b448cca
ToppCell	Children_(3_yrs)-Immune-alveolar_macrophage_(MARCO_positive)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TENM4 ACO1 ACP5 GPCPD1	6.83e-05	188	52	4	d7a9fb5b021e127b8d927658a55a71098d513b5c
ToppCell	3'-Broncho-tracheal-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ACO1 ACP5 GPCPD1 GBP2	6.98e-05	189	52	4	1f4fe19e500bfedd48b1f34827a44e796f6db3e1
ToppCell	3'-Broncho-tracheal-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_CCL3+-Alveolar_macrophage_CCL3+_L.1.0.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ACO1 ACP5 GPCPD1 GBP2	6.98e-05	189	52	4	bfa1dfc93ad33a9dbef316c0591b950d062b35eb
ToppCell	PCW_13-14-Immune_Lymphocytic-Immune_Lymphocytic_NK/ILC-im_ILC2_(21)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	THEMIS PIK3CG GBP2 TXK	6.98e-05	189	52	4	620d5a71b8cb6288540e2d2d848b9d4d66c1226f
ToppCell	Fetal_29-31_weeks-Immune-T_lymphocyte-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	TNIK THEMIS GBP2 TXK	7.12e-05	190	52	4	2a8de1cf27a9ebc3825cf9e7a489ecd064dfc7f9
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_T\|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)	TNIK THEMIS NXPE3 TXK	7.27e-05	191	52	4	9bb6a6b88f351217455765ba07a6acf11fda98f4
ToppCell	facs-Trachea-nan-3m-Lymphocytic\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ATAD5 CDK1 TXK	7.27e-05	191	52	4	89eb4e30052d0d4a2952157ca743291900ce8de2
ToppCell	facs-Trachea-nan-3m-Lymphocytic-T_cell\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ATAD5 CDK1 TXK	7.27e-05	191	52	4	0bf575eba311745fb75f9523f7fc81f73848e25d
ToppCell	facs-Trachea-nan-3m-Lymphocytic-nan\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	THEMIS ATAD5 CDK1 TXK	7.27e-05	191	52	4	c57df363e3a6e61d2bdca1955330f1899b964267
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell\|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)	TNIK THEMIS NXPE3 TXK	7.41e-05	192	52	4	1c0ce299cee9ab5cdea256f3e8c1e5598577a8b6
ToppCell	10x5'v1-week_14-16-Lymphocytic_T-T_NK-NK_T_cell\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	TNIK THEMIS GBP2 TXK	7.41e-05	192	52	4	e836e3e4f419acdca106bc666c3c687f02da2fb3
ToppCell	Severe-Myeloid-Macrophages-FABP4+\|Severe / Condition, Lineage, Cell class and cell subclass	DNASE2B ACO1 ACP5 RYR1	7.41e-05	192	52	4	30aad927ad40d8abaf9d0539bf8cb9d88d16f24d
ToppCell	facs-Thymus-Flowthrough-3m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATAD5 CDK1 ERI1 CDK2	7.41e-05	192	52	4	e8d47504b744040a762ec9b670a66cc060b2ae86
ToppCell	COVID-19-Fibroblasts-Other_FB\|COVID-19 / group, cell type (main and fine annotations)	TENM4 LRRTM4 MMP2 KCNB2	7.56e-05	193	52	4	e6b75be08e33c1de079fb5c02f0b4468128b369c
ToppCell	PCW_13-14-Immune_Lymphocytic-Immune_Lymphocytic_B-im_lymphoid_progenitor_(7)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	THEMIS PIK3CG GBP2 TXK	7.72e-05	194	52	4	69f7bedf6f0be338e4317c22125e727fb82000fc
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic-lymphocyte-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	ATAD5 ACO1 CDK1 ERI1	7.72e-05	194	52	4	8f4b63b0b9a40765205e4ca6bd94a675a83dbe3d
ToppCell	PCW_13-14-Immune_Lymphocytic\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	THEMIS PIK3CG GBP2 TXK	7.72e-05	194	52	4	36678999d0c1c5b0aab206fec7a8c36a0f43c56a
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-T_cells-TRGV2_gdT\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	THEMIS GYG1 ACP5 TXK	7.72e-05	194	52	4	4b208bb429a1e3d58a9b757b05ef4df85a1e7f1e
ToppCell	Control-Neu_4\|Control / 5 Neutrophil clusters in COVID-19 patients	GYG1 LRRTM4 DCLRE1B NXPE3	8.03e-05	196	52	4	b8b7b54ca17a08fa775507bb22b1c7248ada8f40
ToppCell	Bronchial-NucSeq-Immune_Myeloid-Mast_cell-Mast_cell\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TNIK ST8SIA6 FERMT1 RYR3	8.19e-05	197	52	4	bed8a9b73af5caee51b1232b31c24a59353658df
ToppCell	Bronchial-NucSeq-Immune_Myeloid-Mast_cell\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	TNIK ST8SIA6 FERMT1 RYR3	8.19e-05	197	52	4	b7d5073d44aa1e2cb83ea8d8104c5ed662665755
ToppCell	LPS_only-Endothelial-Endothelial-FOXM1\|LPS_only / Treatment groups by lineage, cell group, cell type	ATAD5 DHX57 CDK1 RYR1	8.19e-05	197	52	4	038fd92750257d43d5e980fd06d77742b543f11a
ToppCell	Sigmoid-B_cell-B_cell_IgG_Plasma\|B_cell / Region, Cell class and subclass	ST8SIA6 CPEB4 MMP2 RYR3	8.35e-05	198	52	4	305d7ae9b070ac7211638a5282374c02bf13af40
ToppCell	Mild-CD8+_T_activated\|Mild / Disease group and Cell class	THEMIS GPBP1 GBP2 MCOLN2	8.35e-05	198	52	4	ceac1b51bacfd0dd7fe7c6a666f7927055e1f380
ToppCell	Caecum-T_cell-Treg\|T_cell / Region, Cell class and subclass	TNIK PRDM8 ACP5 GBP2	8.35e-05	198	52	4	90a2a75ca078f7088b8739795a9b396113bcbe23
ToppCell	Bronchial-10x5prime-Immune_Myeloid-Macrophage_alveolar-Macro_alv_dividing\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	ACP5 GPCPD1 CDK1 ERI1	8.51e-05	199	52	4	e1190b1c2d21fed313bb58e24d0e6365de6e6599
ToppCell	mLN-T_cell\|mLN / Region, Cell class and subclass	TNIK THEMIS GBP2 TXK	8.51e-05	199	52	4	caa37ec509b54e842564d754f100ab1b2a77a7c1
ToppCell	Mild-Myeloid-Macrophages-FABP4+\|Mild / Condition, Lineage, Cell class and cell subclass	DNASE2B ACO1 ACP5 GPCPD1	8.51e-05	199	52	4	7bfd6ca4b0f2683715c24dfd7cf40418b5b8ddf2
ToppCell	mLN-(1)_T_cell\|mLN / shred on region, Cell_type, and subtype	TNIK THEMIS GBP2 TXK	8.51e-05	199	52	4	4bf2641409c543c2167bff71efa95b00dd7bfe19
ToppCell	primary_visual_cortex-Non-neuronal-leptomeningeal_cell-VLMC-VLMC_Osr1_Cd74\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	THEMIS GBP2 MCOLN2	3.28e-04	115	52	3	4c7d78a246f1b44846fb959359515ef185530053
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L5_PT-L5_PT_ALM_Hpgd\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	BCL6 RYR1 RYR3	4.29e-04	126	52	3	9b04ca8a46cc30119baf6ef27711a0b2a6b4a0c9
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L5_PT-L5_PT_VISp_C1ql2_Ptgfr\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	BCL6 RYR1 RYR3	4.39e-04	127	52	3	fb58f4b4d3722f4b9a2e4946c0244c5b70dd883b
ToppCell	Lymphoid-T_cells_(Cd4+_Tnaive-Tcm)\|World / shred on cell class and cell subclass (v4)	THEMIS ACP5 TXK	4.91e-04	132	52	3	14a371fc7e47a45b84f10a939163d030ad967de5
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L5_PT\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	BCL6 RYR1 RYR3	5.13e-04	134	52	3	cb676d5bbc468bd3ce1b6712d41c986ee9221ac5
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L5_PT-L5_PT_VISp_C1ql2_Cdh13\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	BCL6 RYR1 RYR3	5.36e-04	136	52	3	1f3000d5f105c87c80f8ae1dd2264bcd7f757a9c
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-L5_PT\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	BCL6 RYR1 RYR3	5.83e-04	140	52	3	7cc891d676555609add6fc7880735d948a2ad801
ToppCell	Posterior_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	LRRTM4 KCNB2 RYR1	6.20e-04	143	52	3	5fb5a4ea93e5cce55d427e3b4a50a979504fad3c
ToppCell	Posterior_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1-Bcl6\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	BCL6 RYR1 RYR3	6.33e-04	144	52	3	08005be9e3367f78ef27e125d9cce5ca53f4bd2d
ToppCell	Adult-Immune-dendritic_cell-D231\|Adult / Lineage, Cell type, age group and donor	PIK3CG BCL6 MCOLN2	6.72e-04	147	52	3	7cc4f74dd7a86247db8dc049ed7eadeb53825a96
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c05-FOS\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	TNIK THEMIS TXK	6.72e-04	147	52	3	463af96748349c8fec2911b353a7e7e4cb072280
ToppCell	E16.5-samps-Myeloid-Fetal_macrophage-macrophage_-_intermediate_-_unactivated\|E16.5-samps / Age Group, Lineage, Cell class and subclass	PIK3CG CPEB4 APOB	7.12e-04	150	52	3	60fdd266aaca1b589b9a77465a4a7fad4921339a
ToppCell	RV-17._Lymphocyte\|RV / Chamber and Cluster_Paper	TDRD15 THEMIS TXK	7.54e-04	153	52	3	e1ea621184014415870e00d511386b8cc3e0833b
ToppCell	3'_v3-GI_small-bowel-Lymphocytic_T_CD4-Tregs\|GI_small-bowel / Manually curated celltypes from each tissue	TNIK GBP2 RYR1	7.83e-04	155	52	3	d4ef25965a15eab7679478b9b661e1b4a92f1c59
ToppCell	RV-17._Lymphocyte\|World / Chamber and Cluster_Paper	TDRD15 THEMIS TXK	7.83e-04	155	52	3	189276a3b400b2202e6681e23732e6452bfe704e
ToppCell	10x5'-bone_marrow-Lymphocytic_T_CD4-T_CD4/CD8\|bone_marrow / Manually curated celltypes from each tissue	LRRTM4 GPCPD1 MCOLN2	7.98e-04	156	52	3	1545169694f686d28648a68b552c2ae606599d66
ToppCell	5'-Adult-Appendix-Hematopoietic-B_cells-Cycling_B_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	BCL6 SERPINA9 MCOLN2	7.98e-04	156	52	3	203ef22eb76bd2b829b027c30af0557080f4006c
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-myeloid-myeloid_macrophage-Langerhans_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	CDK2 MCOLN2 CC2D2B	8.13e-04	157	52	3	10341ed8cbee0f636770a82cf580f6453bee8596
Drug	5'-adenylyl (beta,gamma-methylene)diphosphonate	RYR1 RYR3	4.92e-06	2	51	2	ctd:C005147
Drug	BMS-265246	CDK1 CDK2	4.92e-06	2	51	2	CID005329775
Drug	SQ-67563	CDK1 CDK2	4.92e-06	2	51	2	CID005329767
Drug	AC1O5R58	CDK1 CDK2	4.92e-06	2	51	2	CID006439178
Drug	succinylcholine	DMWD PLEKHM1 RYR1 RYR3	1.28e-05	64	51	4	CID000005314
Drug	Hymenialdisine	CDK1 CDK2	1.47e-05	3	51	2	DB02950
Drug	2-hydroxycarbazole	RYR1 RYR3	1.47e-05	3	51	2	CID000093551
Drug	1,1'-diheptyl-4,4'-bipyridinium	RYR1 RYR3	1.47e-05	3	51	2	CID000080262
Drug	cis-diammineplatinum(II	RYR1 RYR3	1.47e-05	3	51	2	CID000159790
Drug	2-hydroxyheptanoic acid	RYR1 RYR3	1.47e-05	3	51	2	CID002750949
Drug	flubendiamide	RYR1 RYR3	1.47e-05	3	51	2	CID011193251
Drug	Ryanodyl 3-(pyridine-3-carboxylate	RYR1 RYR3	1.47e-05	3	51	2	CID005748312
Drug	8N3-cADPR	RYR1 RYR3	1.47e-05	3	51	2	CID000127713
Drug	SU9516	CDK1 CDK2	1.47e-05	3	51	2	DB03428
Drug	aminodantrolene	RYR1 RYR3	1.47e-05	3	51	2	CID009570289
Drug	Alsterpaullone	CDK1 CDK2	2.94e-05	4	51	2	DB04014
Drug	A-30	RYR1 RYR3	2.94e-05	4	51	2	CID003028528
Drug	PCB74	RYR1 RYR3	2.94e-05	4	51	2	CID000036218
Drug	NW-1	CDK1 CDK2	2.94e-05	4	51	2	CID000398148
Drug	148504-47-6	RYR1 RYR3	2.94e-05	4	51	2	CID006444275
Drug	Bastadin 10	RYR1 RYR3	2.94e-05	4	51	2	CID009589366
Drug	SC 38249	RYR1 RYR3	2.94e-05	4	51	2	CID000134834
Drug	Olomoucine	CDK1 CDK2	2.94e-05	4	51	2	DB02116
Drug	Indirubin-3'-Monoxime	CDK1 CDK2	2.94e-05	4	51	2	DB02052
Drug	AC1L1U7A	RYR1 RYR3	2.94e-05	4	51	2	CID000035682
Drug	NSC645787	CDK1 CDK2	2.94e-05	4	51	2	CID000438541
Drug	NG97	CDK1 MMP2 CDK2	4.12e-05	30	51	3	CID006604931
Drug	NU2058	CDK1 CDK2	4.90e-05	5	51	2	ctd:C466913
Drug	Pyrazolopyridazine 1a	CDK1 CDK2	4.90e-05	5	51	2	CID006263849
Drug	SNS-032	CDK1 MMP2 CDK2	6.03e-05	34	51	3	CID003025986
Drug	MBED	RYR1 RYR3	7.34e-05	6	51	2	CID000129958
Drug	chloro-m-cresol	RYR1 RYR3	7.34e-05	6	51	2	CID000012008
Drug	thioacridone	CDK1 CDK2	7.34e-05	6	51	2	CID002818474
Drug	AC1O528X	RYR1 RYR3	7.34e-05	6	51	2	CID006475857
Drug	NSC114784	RYR1 RYR3	7.34e-05	6	51	2	CID000419425
Drug	NSC692750	RYR1 RYR3	7.34e-05	6	51	2	CID000078910
Drug	PD179483	CDK1 CDK2	7.34e-05	6	51	2	CID005330526
Drug	fludrocortisone acetate; Up 200; 1uM; MCF7; HG-U133A	DHX57 BCL6 KCNB2 DMWD USP48	7.84e-05	197	51	5	281_UP
Drug	pioglitazone	PIK3CG APOB MMP2 RYR1 RYR3 CDK2	8.62e-05	326	51	6	CID000004829
Drug	AC1L50UZ	MMP2 PLEKHM1	1.03e-04	7	51	2	CID000167927
Drug	Azumoleno	RYR1 RYR3	1.03e-04	7	51	2	CID000056259
Drug	mag-indo-1	RYR1 RYR3	1.03e-04	7	51	2	CID000131881
Drug	linarin	CDK1 CDK2	1.03e-04	7	51	2	CID005317025
Drug	Br2BAPTA	RYR1 RYR3	1.03e-04	7	51	2	CID003081001
Drug	isothiazolidine-1,1-dioxide	CDK1 CDK2	1.03e-04	7	51	2	CID000642157
Drug	4 SP	CDK1 CDK2	1.03e-04	7	51	2	CID000004566
Drug	olomoucine	CDK1 CDK2	1.03e-04	7	51	2	ctd:C090046
Drug	[[(2R,3S,4R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate	RYR1 RYR3	1.03e-04	7	51	2	CID009547999
Drug	CHEBI:564108	RYR1 RYR3	1.03e-04	7	51	2	CID006400637
Drug	ZD 9331	CDK1 CDK2	1.37e-04	8	51	2	ctd:C094299
Drug	AG-012986	CDK1 CDK2	1.37e-04	8	51	2	ctd:C512484
Drug	NU2058	CDK1 CDK2	1.37e-04	8	51	2	CID000004564
Drug	ogen	CYP3A43 SERPINC1 MMP2	1.50e-04	46	51	3	CID000023703
Drug	lactosyl lysosphingolipid	RYR1 RYR3	1.75e-04	9	51	2	CID006439268
Drug	CVT-313	CDK1 CDK2	1.75e-04	9	51	2	CID006918386
Drug	FLA 365	RYR1 RYR3	1.75e-04	9	51	2	CID000072776
Drug	etridiazole	GYG1 RYR1 RYR3	1.93e-04	50	51	3	CID000017432
Drug	retigeric acid B	CDK1 CDK2	2.19e-04	10	51	2	ctd:C540615
Drug	Flavopiridol	CDK1 CDK2	2.19e-04	10	51	2	DB03496
Drug	AC1N38XE	RYR1 RYR3	2.19e-04	10	51	2	CID004060965
Drug	PCB 95	RYR1 RYR3	2.19e-04	10	51	2	CID000038012
Drug	kuguacin J	MMP2 CDK2	2.67e-04	11	51	2	ctd:C572783
Drug	PCB 66	RYR1 RYR3	2.67e-04	11	51	2	CID000036185
Drug	R 478	RYR1 RYR3	2.67e-04	11	51	2	CID000084223
Drug	8-amino-cADPR	RYR1 RYR3	2.67e-04	11	51	2	CID003081323
Drug	2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide	CDK1 CDK2	2.67e-04	11	51	2	ctd:C488185
Drug	Ryanodine	RYR1 RYR3	3.20e-04	12	51	2	ctd:D012433
Drug	AS 4	CDK1 MMP2	3.20e-04	12	51	2	CID000139279
Drug	liposomal doxorubicin	CDK1 CDK2	3.20e-04	12	51	2	ctd:C506643
Drug	Staurosporine	PIK3CG CDK2	3.20e-04	12	51	2	DB02010
Drug	wortmannin	PIK3CG APOB CDK1 MMP2 CDK2	3.23e-04	267	51	5	ctd:C009687
Drug	selenite	MMP2 RYR1 RYR3 CDK2	3.38e-04	148	51	4	CID000001090
Drug	manganese	ACO1 GYG1 ACP5 MMP2 RYR1 RYR3 CDK2 TXK	3.47e-04	791	51	8	CID000023930
Drug	tetrahydroneopterin	APOB MMP2	3.78e-04	13	51	2	CID000161510
Drug	NSC299933	RYR1 RYR3	3.78e-04	13	51	2	CID000431902
Drug	aloisine A	CDK1 CDK2	3.78e-04	13	51	2	CID005326843
Drug	2,3-dichlorophenoxyacetic acid	CDK1 CDK2	3.78e-04	13	51	2	CID000018105
Drug	diacerein	ACO1 MMP2 MMP20	3.82e-04	63	51	3	CID000026248
Drug	lercanidipine	MMP2 RYR1 RYR3	3.82e-04	63	51	3	CID000065866
Drug	isoflavone	CDK1 MMP2 MMP20 CDK2	4.03e-04	155	51	4	CID000072304
Drug	bimoclomol	RYR1 RYR3	4.40e-04	14	51	2	CID009576891
Drug	fascaplysine	MMP2 CDK2	4.40e-04	14	51	2	ctd:C069346
Drug	7-benzylamino-5-(2-(hydroxymethyl)propyl)amino-3-isopropyl-1(2)H-pyrazolo(4,3-d)pyrimidine	CDK1 CDK2	4.40e-04	14	51	2	ctd:C559145
Drug	AC1L9FYY	CDK1 CDK2	4.40e-04	14	51	2	CID000444231
Drug	NP-EGTA	RYR1 RYR3	4.40e-04	14	51	2	CID000183793
Disease	congenital myopathy 1A (implicated_via_orthology)	RYR1 RYR3	9.13e-06	3	52	2	DOID:3529 (implicated_via_orthology)
Disease	malignant hyperthermia (implicated_via_orthology)	RYR1 RYR3	9.13e-06	3	52	2	DOID:8545 (implicated_via_orthology)
Disease	esterified cholesterol measurement, intermediate density lipoprotein measurement	TDRD15 APOB	8.47e-05	8	52	2	EFO_0008589, EFO_0008595
Disease	diffuse large B-cell lymphoma (is_marker_for)	BCL6 DICER1	8.47e-05	8	52	2	DOID:0050745 (is_marker_for)
Disease	Diffuse Large B-Cell Lymphoma	PIK3CG CDK1 CDK2	1.27e-04	55	52	3	C0079744
Disease	common carotid intimal medial thickness	TDRD15 APOB RYR3	2.28e-04	67	52	3	EFO_0004860
Disease	esterified cholesterol measurement, low density lipoprotein cholesterol measurement	TDRD15 APOB	2.73e-04	14	52	2	EFO_0004611, EFO_0008589
Disease	low density lipoprotein triglyceride measurement	TDRD15 APOB	3.15e-04	15	52	2	EFO_0009946
Disease	response to statin, LDL cholesterol change measurement	TDRD15 APOB	3.15e-04	15	52	2	EFO_0007804, GO_0036273
Disease	cholesterol to total lipids in chylomicrons and extremely large VLDL percentage	TDRD15 APOB	4.07e-04	17	52	2	EFO_0022232
Disease	very low density lipoprotein cholesterol measurement, esterified cholesterol measurement	TDRD15 APOB	4.58e-04	18	52	2	EFO_0008317, EFO_0008589
Disease	response to anticonvulsant	TDRD15 PIK3CG LRRTM4	4.60e-04	85	52	3	GO_0036277
Disease	white matter microstructure measurement	TNIK APOB ERI1 BCL6 PLEKHM1	6.13e-04	390	52	5	EFO_0005674
Disease	proprotein convertase subtilisin/kexin type 9 measurement	TDRD15 APOB	6.88e-04	22	52	2	EFO_0009312
Disease	nephrotic syndrome (biomarker_via_orthology)	SERPINC1 APOB	8.20e-04	24	52	2	DOID:1184 (biomarker_via_orthology)
Disease	level of Sterol ester (27:1/18:2) in blood serum	TDRD15 APOB	9.64e-04	26	52	2	OBA_2045194
Disease	coronary artery disease, factor VII measurement	TDRD15 PRDM8 APOB	1.00e-03	111	52	3	EFO_0001645, EFO_0004619
Disease	lipoprotein A measurement	TDRD15 GPCPD1 APOB	1.03e-03	112	52	3	EFO_0006925
Disease	cholesterol to total lipids in medium LDL percentage	TDRD15 APOB	1.04e-03	27	52	2	EFO_0022238
Disease	factor VIII measurement, coronary artery disease	TDRD15 PRDM8 APOB	1.05e-03	113	52	3	EFO_0001645, EFO_0004630
Disease	susceptibility to rheumatic fever measurement	KCNB2 RYR3	1.12e-03	28	52	2	EFO_0008416
Disease	Cerebral Hemorrhage	SERPINC1 MMP2	1.12e-03	28	52	2	C2937358
Disease	von Willebrand factor measurement, coronary artery disease	TDRD15 PRDM8 APOB	1.19e-03	118	52	3	EFO_0001645, EFO_0004629
Disease	cardiovascular disease	TDRD15 PRDM8 CPEB4 APOB DCLRE1B	1.25e-03	457	52	5	EFO_0000319
Disease	low density lipoprotein cholesterol measurement, phospholipid measurement	TDRD15 APOB DMWD	1.25e-03	120	52	3	EFO_0004611, EFO_0004639
Disease	arteriosclerosis (is_implicated_in)	APOB MMP2	1.37e-03	31	52	2	DOID:2349 (is_implicated_in)
Disease	triglyceride measurement, high density lipoprotein cholesterol measurement	TDRD15 TENM4 APOB SERPINA9	1.39e-03	274	52	4	EFO_0004530, EFO_0004612
Disease	word list delayed recall measurement, memory performance	TENM4 LRRTM4	1.55e-03	33	52	2	EFO_0004874, EFO_0006805

Protein segments in the cluster

Peptide	Gene	Start	Entry
WNSKSTYIKSPPFFE	ACO1	636	P21399
IRWSNPEFSLKKYFP	ATAD5	951	Q96QE3
PPFAKKWINIRKSYG	ERI1	251	Q8IV48
PKAFKQYWFIFKDTS	FERMT1	386	Q9BQL6
IYFKGLWKSKFSPEN	SERPINC1	251	P01008
PADFRYPNLDFGWKK	DICER1	1086	Q9UPY3
FDYSKESFWKQLLPK	CC2D2B	1271	Q6DHV5
FPDLYSKEWNKAVPF	DCLRE1B	401	Q9H816
YAAKSKAPRNPLAKW	DMWD	266	Q09019
SKWSPPQNYKKRVAA	ZFYVE19	141	Q96K21
DVANYNFFPRKPKWD	MMP2	106	P08253
VYPNWKKFSTFTEAP	LEXM	41	Q3ZCV2
PLFYWLKNFKGNKES	LRRTM4	321	Q86VH4
FKFGPWKNSTFKPTT	GPBP1	441	Q86WP2
KFFPKRKCFVFDWPA	GBP2	226	P32456
RKCFVFDWPAPKKYL	GBP2	231	P32456
RYKKKWAATEPKFPA	NSUN4	26	Q96CB9
EFYQKKKSRWPFSDE	ATG101	101	Q9BSB4
KWNFYYSPQSSPDKK	APOB	4021	P04114
KSSFSKYWKPRIPLD	GPCPD1	306	Q9NPB8
RVKPWNYTYDPKTKS	GYG1	216	P46976
RFLSSPNKWKFFKGP	KCNB2	251	Q92953
FYDHEAFWTPLKKPK	C2CD3	1441	Q4AC94
DWFTFYKLPKRQNKE	DNASE2B	41	Q8WZ79
KYWTEPEKFCPERFS	CYP3A43	406	Q9HB55
LAFKSPFVSPWDKKE	DHX57	1091	Q6P158
SPTDPKACNWKKYKF	BCL6	366	P41182
SWTKFPNIPYKRAFS	KLHDC8A	201	Q8IYD2
SYLAWYQQKPGKAPK	IGKV1-8	51	A0A0C4DH67
QKYARPSSAFAPKSW	CPEB4	346	Q17RY0
YKPSFPKWARQDFSK	CDK2	236	P24941
SFPSNYWDKFVKRKV	RYR1	4711	P21817
KPPDWKNSSFFRLEF	MCOLN2	201	Q8IZK6
ANYRLFPGEPKWKKN	MMP20	106	O60882
FPGEPKWKKNTLTYR	MMP20	111	O60882
QFYSKAKTYWKQIPP	NTMT1	11	Q9BV86
PKNKSWISEDDFYRP	PLEKHM1	436	Q9Y4G2
PVGEKWSPKALNYFK	TDRD15	131	B5MCY1
LYTGEPWFCFKPKKL	NXPE3	241	Q969Y0
KQSPFLYATAFWPKS	PRDM8	571	Q9NQV8
KNVKLYGFWPFSKTV	ST8SIA6	336	P61647
SNFGPVWYVPDKKKA	SHROOM2	296	Q13796
LPKYFSSKWSFSKFQ	WDR45B	276	Q5MNZ6
KNWAARQPEPTKFDY	NDUFAF5	56	Q5TEU4
KWEKPFHPEYTRKNF	SERPINA9	211	Q86WD7
DYKNTFPKWKPGSLA	CDK1	236	P06493
PKAYPKLFSSVKWGQ	PIK3CG	586	P48736
SNKWDSTNPFPKDFY	THEMIS	206	Q8N1K5
WAPKPYHKFMAFKSF	TNIK	1171	Q9UKE5
NTPSFPNNYWDKFVK	RYR3	4541	Q15413
TTPDCRKKFWKNYFV	SLC24A5	321	Q71RS6
IAYSKISKRWNFPSP	ACP5	121	P13686
PAFNLKKPSKYCNWK	TENM4	326	Q6N022
KWSPPEVFLFNKYSS	TXK	431	P42681
AWSKLQQYFPKAPEF	USP48	671	Q86UV5